Trial reportPloS one2021
Nutritional markers and proteome in patients undergoing treatment for pulmonary tuberculosis differ by geographic region.
Trial report in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT00694629 (TBTC Study 29), which is not on this map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
TBTC Study 29: Evaluation of a Rifapentine-containing Regimen for Intensive Phase Treatment of Pulmonary Tuberculosis
Who cites it
10 citing papers in PubMed, 11 citations in OpenAlex.
- Human Tuberculosis in Migrant and Autocthonous Patients: A Ten-Year Single-Centre Experience.Pathogens (Basel, Switzerland) · 2025Article
- Review
- Correction: Nutritional markers and proteome in patients undergoing treatment for pulmonary tuberculosis differ by geographic region.PloS one · 2025Article
- Metabolite dynamics over the course of anti-tuberculosis treatment in individuals with mild and severe tuberculosis.PLOS global public health · 2025Article
- Molecular profiles of blood from numerous species that differ in sensitivity to acute inflammation.Molecular medicine (Cambridge, Mass.) · 2024Article
- Longitudinal analysis of host protein serum signatures of treatment and recovery in pulmonary tuberculosis.PloS one · 2024Article
- Multi-Omic blood analysis reveals differences in innate inflammatory sensitivity between species.medRxiv : the preprint server for health sciences · 2023Article
- Proteomic-based identification of APCS as candidate protein for diagnosis of patients exhibiting anti-tubercular drug induced liver injury.Scientific reports · 2023Article
- Article
- AllCurrent research in immunology · 2022Review
Corrections and comments
- Erratum issued
Authors and funding
14 authors at 8 institutions in 2 countries.
Funding
Abstract
introductionContemporary phase 2 TB disease treatment clinical trials have found that microbiologic treatment responses differ between African versus non-African regions, the reasons for which remain unclear. Understanding host and disease phenotypes that may vary by region is important for optimizing curative treatments.
methodsWe characterized clinical features and the serum proteome of phase 2 TB clinical trial participants undergoing treatment for smear positive, culture-confirmed TB, comparing host serum protein expression in clinical trial participants enrolled in African and Non-African regions. Serum samples were collected from 289 participants enrolled in the Centers for Disease Control and Prevention TBTC Study 29 (NCT00694629) at time of enrollment and at the end of the intensive phase (after 40 doses of TB treatment).
resultsAfter a peptide level proteome analysis utilizing a unique liquid chromatography IM-MS platform (LC-IM-MS) and subsequent statistical analysis, a total of 183 core proteins demonstrated significant differences at both baseline and at week 8 timepoints between participants enrolled from African and non-African regions. The majority of the differentially expressed proteins were upregulated in participants from the African region, and included acute phase proteins, mediators of inflammation, as well as coagulation and complement pathways. Downregulated proteins in the African population were primarily linked to nutritional status and lipid metabolism pathways.
conclusionsWe have identified differentially expressed nutrition and lipid pathway proteins by geographic region in TB patients undergoing treatment for pulmonary tuberculosis, which appear to be associated with differential treatment responses. Future TB clinical trials should collect expanded measures of nutritional status and further evaluate the relationship between nutrition and microbiologic treatment response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.